Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Research Article Volume 7 Issue 2

Neurological Manifestations of Mucormycosis in Covid-19

Mohanty SL*, Selvakumar CJ, Sadeeshkumar V and Shobana N

Department of Neurology, Coimbatore Medical College and Hospital, Tamil Nadu, India

*Corresponding Author: Mohanty SL, Department of Neurology, Coimbatore Medical College and Hospital, Tamil Nadu, India.

Received: November 16, 2023; Published: January 10, 2024

Abstract

Background: Mucormycosis has emerged as an opportunistic infection during COVID-19 pandemic. It mostly affects the paranasal sinus, orbits, skin, gastrointestinal tract and brain. Intracranial spread has a poor prognosis and high fatality. It has been termed as “Rhino-orbital-cerebral mucormycosis”.

Objective: To study about the incidence of neurological features of mucormycosis in COVID-19 patients in tertiary care hospital.

Materials and Methods: This is an observational study done in a tertiary care hospital. COVID-19 infection was detected with reverse transcriptase - polymerase chain reaction (RT-PCR). The diagnosis of mucormycosis was confirmed with computed tomography (CT) paranasal sinus, nasal washings and nasal cavity tissue biopsy. CT and magnetic resonance imaging of brain was done.

Results: 30 patients presented with fever, headache, visual loss, decreased sensation over the face, hemiparesis, seizures. The neurological deficits observed were visual loss (n = 12), multiple cranial nerve palsy (n = 20), stroke (arterial = 15, venous = 8), infective encephalopathy (n = 10). The cranial nerves affected were oculomotor, trochlear, abducens (n = 20) followed by optic (n = 12), trigeminal (n = 9) and facial nerve (n = 5). Diabetes mellitus and COVID-19 were the associated risk factors.

Conclusion: There is increasing incidence of neurological complications in mucormycosis during COVID-19 pandemic. Judicious use of corticosteroids, strict hyperglycemic control can help us in reducing the no. of mucormycosis cases and its neurological complications.

Keywords: COVID-19; Rhino-Orbital-Cerebral Mucormycosis; Neurological Manifestations; Amphotericin; Stroke; Orbital Apex

References

  1. K Aleksandr., et al. “A rare indolent course of rhinocerebral mucormycosis”. Case reports in infectious diseases (2021).
  2. K Shamanna., et al. “Rhino-Orbito-Cerebral Mucormycosis: Our Experience”. Research in Otolaryngology 8.2 (2019): 25-29.
  3. YP Talmi., et al. “Rhino-orbital and rhino-orbito-cerebral mucormycosis”. Otolaryngology-Head and Neck Surgery1 (2002): 22-31.
  4. S Mohindra., et al. “Rhinocerebral mucormycosis: the disease spectrum in 27 patients”. Mycoses4 (2007): 290-296.
  5. Gamaletsou MN., et al. “Rhino-orbital- cerebral mucormycosis”. Current Infectious Disease Reports 14 (2012): 423-434.
  6. WC Harril., et al. “Chronic rhinocerebral mucormycosis”. Laryngoscope10 (1996): 1292.
  7. RA Yohai., et al. “Survival factors in rhino-orbital-cerebral mucormycosis”. Survey of Ophthalmology1 (1994): 3.
  8. Rangel Guerra RA., et al. “Rhinocerebral and systemic mucormycosis: clinical experience with 36 cases”. Journal of the Neurological Sciences 143 (1996): 19-30.
  9. HC Pillsbury and ND Fischer. “Rhinocerebral mucormycosis”. Archives of Otorhinolaryngology 10 (1997): 600-604.
  10. Morduchowicz G., et al. “Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature”. Reviews of Infectious Diseases 8 (1986): 441-446.
  11. Gregory JE., et al. “Mucormycosis of the central nervous system”. Bulletin of the John Hopkins Hospital 73 (1943): 405-419.
  12. Pereira, et al. “Rhino-orbital mucormycosis: report of a case”. Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 37.3 (1982): 140-146.
  13. Ambrosio A and Alterio F. “A case of rhino-orbital mucormycosis in a subject with compensated diabetes mellitus”. Minerva Stomatologica 11 (1994): 543-548.
  14. Reddy SS., et al. “Rhinocerebral Mucormycosis Among Diabetic Patients: An Emerging Trend”. Mycopathologia5-6 (2015): 389-396.
  15. Peterson KL., et al. “Rhinocerebral mucormycosis: evolution of the disease and treatment options”. Laryngoscope 107 (1997): 855-862.
  16. Yanagisawa E., et al. “Rhinocerebral phycomycosis”. Laryngoscope 87 (1977): 1319-1335.
  17. Toumi A., et al. “Rhino-orbito-cerebral mucormycosis: five cases”. Médecine et Maladies Infectieuses 12 (2012): 591-598.

Citation

Citation: Mohanty SL., et al. “Neurological Manifestations of Mucormycosis in Covid-19" Acta Scientific Neurology 7.2 (2024): 14-18.

Copyright

Copyright: © 2024 Mohanty SL., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US